Search

Search Constraints

You searched for: Author/Creator Gopal, Ajay K.

Search Results

1. A phase I study of pulse high‐dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. (29th January 2013)

2. A phase II trial evaluating the efficacy of high‐dose Radioiodinated Tositumomab (Anti‐CD20) antibody, etoposide and cyclophosphamide followed by autologous transplantation, for high‐risk relapsed or refractory non‐hodgkin lymphoma. Issue 7 (22nd April 2020)

3. A pilot study of weekly brentuximab vedotin in patients with CD30+ malignancies resistant to brentuximab vedotin every 3 weeks. (28th December 2018)

4. Addressing the conundrum of male predominance in mantle cell lymphoma using androgen receptor blockade. (22nd June 2020)

5. Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Issue 3 (March 2015)

6. Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. Issue 1 (January 2015)

7. Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial. (14th September 2018)

8. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Issue 9 (October 2015)

9. Bortezomib and fenretinide induce synergistic cytotoxicity in mantle cell lymphoma through apoptosis, cell-cycle dysregulation, and IκBα kinase downregulation. Issue 9 (October 2015)

10. Brentuximab vedotin administered to platinum‐refractory, transplant‐naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Issue 4 (18th September 2014)